Last $6.33 USD
Change Today -0.01 / -0.16%
Volume 444.1K
ECYT On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:36 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Snapshot

Open
$6.18
Previous Close
$6.34
Day High
$6.42
Day Low
$6.16
52 Week High
03/21/14 - $33.70
52 Week Low
05/20/14 - $6.01
Market Cap
261.9M
Average Volume 10 Days
1.1M
EPS TTM
$-0.48
Shares Outstanding
41.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOCYTE INC (ECYT)

endocyte inc (ECYT) Related Businessweek News

No Related Businessweek News Found

endocyte inc (ECYT) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

91 Employees
Last Reported Date: 03/5/14
Founded in 1995

endocyte inc (ECYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $722.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $434.4K
Executive Officer
Total Annual Compensation: $477.8K
Vice President of Clinical Affairs
Total Annual Compensation: $435.6K
Compensation as of Fiscal Year 2013.

endocyte inc (ECYT) Key Developments

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Endocyte, Inc

Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been filed in the United States District Court for the Southern District of Indiana on behalf of a comprising all purchasers of the common stock of Endocyte, Inc. between March 21, 2014 and May 2, 2014. On May 2, 2014, Endocyte disclosed that VYNFINIT was found ineffective in the treatment of platinum-resistant ovarian cancer, based on certain testing methods known as response evaluation criteria in solid tumors, or 'RECIST'. Following this news, on May 2, 2014, the price of Endocyte stock dropped approximately 61% from the previous day's closing price, to close at $6.62 per share on May 2, 2014, on unusually heavy trading volume. The company subsequently announced that it would withdraw its application to market VYNFINIT in Europe.

Endocyte Regains Worldwide Rights to Vintafolide

Endocyte, Inc. announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide. Endocyte will evaluate vintafolide for future development opportunities pending final results from the Phase 2b TARGET trial in patients with non-small cell lung cancer (NSCLC). The companies announced in March that the TARGET trial met its primary progression-free-survival (PFS) endpoint and overall response rates and early overall survival (OS) trends were positive. Neither company has received updated overall survival data since that announcement.

Endocyte, Inc. Appoints Michael A. Sherman as Chief Operating Officer

On June 16, 2014, the Board of Directors of Endocyte, Inc. appointed Michael A. Sherman, currently the company's Chief Financial Officer, to the newly-created position of Chief Operating Officer of the company. Mr. Sherman will assume responsibility for additional operational functions at the company, and he will continue to also serve as the Chief Financial Officer of the company. Mr. Sherman, age 48, has served as the company's Chief Financial Officer since October 2006.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $6.33 USD -0.01

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies
 

Industry Analysis

ECYT

Industry Average

Valuation ECYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.